New Delhi: Drug firm Wockhardt expects its several new antibiotic drugs that are under development as positive factors that will impact the shape of things to come, according to the companys Founder Chairman Habil Khorakiwala. In his address to shareholders in the Annual Report for 2018-19, Khorakiwala said the company has several new chemical entities (NCEs) which are being developed as antibiotic drugs that are at various stages of clinical trials. "I believe that the development work on these drugs today will shape the global war on Antimicrobial Resistance (AMR) tomorrow," he added. Khorakiwala said Wockhardts NCE, WCK 4282, has been acknowledged by Chinese regulator National Medical Products Administration (NMPA) that the product would address unmet needs in China. Accordingly, China would be a part of the global Phase III cUTI (complicated urinary tract infection) study. He further said another NCE, WCK 4873, has obtained India phase 3 CABP (Community-acquired Bacterial Pneumonia) study approval from the countrys drug regulator Drug Controller General of India (DCGI). The study will commence in the third quarter of 2019.